This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)

VIDEO: How do the leading COVID vaccines differ? And what does that mean for Canada?

All three of the drug companies are incorporating novel techniques in developing their vaccines

On Monday AstraZeneca became the third pharmaceutical company this month to announce promising results from a late-stage coronavirus vaccine clinical trial, joining Pfizer and Moderna as the leading candidates for developing an effective prevention for COVID-19.

While all promise a suitable vaccine can be rolled out within the coming months, they differ slightly in efficacy, delivery and other components.

So how do we judge the leading candidates so far, and how might they impact a vaccine rollout program in Canada?

The Canadian Press asked Kelly Grindrod, an associate professor at the University of Waterloo’s School of Pharmacy, and Dr. Earl Brown, a virology and microbiology expert at the University of Ottawa, to break down those questions.

HOW DO THEY WORK?

All three of the drug companies are incorporating novel techniques in developing their vaccines, with Pfizer and Moderna using messenger RNA (mRNA) and AstraZeneca using a non-replicating viral vector.

AstraZeneca’s vaccine, developed with Oxford University, takes a chimpanzee cold virus that’s not harmful to humans and “hides” pieces of the coronavirus in it, Grindrod explained. Non-replicating means the virus won’t actually reproduce throughout the body.

“It shows our cells how to make the coronavirus spike protein so that our bodies can actually have an immune response to it,” she said.

Brown explained it as a “dummy virus” that has essentially had its genes stripped and replaced with the spike protein gene for the coronavirus. The vaccine makes an mRNA molecule from the genome and that molecule makes the protein, he said.

“The protein is put on the cell, the immune system recognizes it and makes antibodies — therefore immunity.”

The mRNA vaccines are similar, but structurally different with Brown simplifying it by saying Pfizer and Moderna “put the RNA right into your arm.”

“Their vaccine is a synthetically-produced mRNA packaged in a fat coating,” he said. “So they inject that into your muscles, that little fat gloms onto your cells, fuses with them and becomes part of the cell and dumps that mRNA into your cell. And then the mRNA is translated into protein.”

Grindrod said both vaccine methods “show us the genetic component” our cells need to make the antibodies.

“It’s just really how it’s delivered,” she added.

HOW EFFECTIVE ARE THEY?

AstraZeneca says its vaccine was up to 90 per cent effective when a half dose was followed by a full dose a month later. Another method, where two full doses were distributed a month apart, showed to be 62 per cent effective.

Moderna said last week that preliminary data showed a 94.5 per cent efficacy, and Pfizer, the first to share its initial results earlier this month, upped theirs from 90 to 95 after releasing final trial results last week.

While the medical journal “The Lancet” did review some of AstraZeneca’s results, Grindrod says to remember that most of the efficacy claims from the clinical trials are from press releases based off preliminary data.

“Now what we’re waiting for is the actual study, the full published, peer review that you can see and compare efficacy and safety and how they measured it,” she said, adding she expects peer-reviewed studies on the vaccines to emerge soon.

“Things are coming at much different timelines than we’re used to.”

Another factor that’s still unknown is how long immunity lasts, and whether we will need booster vaccines in the future.

WHAT ARE THE HURDLES FACING DISTRIBUTION?

All three of the leading vaccine candidates require two doses, injected roughly one month apart, and there could be challenges in getting people back to a doctor or pharmacy to receive their second dose.

Grindrod said tracking will become particularly important with a two-dose vaccine, especially if AstraZeneca goes forward with injecting different amounts of the vaccine per dose. Rollout can become even more complicated when there’s a surge for the vaccine, as we saw this year with the flu shot.

“You have to track who got which vaccine, which dose, and make sure they come back three to four weeks later,” she said.

Where AstraZeneca could have the upper hand in distribution, however, is in its storage temperature. The company says its vaccine can be stored in a fridge, unlike Moderna and Pfizer, which require freezing temperatures due to the instability of the mRNA, Brown says.

Pfizer’s vaccine needs to be stored at minus-70 C, while Moderna’s needs a temperature around minus-20 C — about the same as a regular freezer.

“For really ultra-low temperature freezers, you find those in hospitals and research laboratories, but not many other places,” Brown said. “So we aren’t prepared for (a vaccine that requires) ultra low freezers.”

READ MORE: 3rd major COVID-19 vaccine shown to be effective and cheaper

ARE THERE ANY SIDE EFFECTS?

Side effects for all three vaccines have been minimal — things like sore arms, fatigue and headaches that generally don’t last long — and Brown says the presence of those reactions are a good thing.

“When you’re vaccinating, you’re stimulating an immune response, and those are immune-regulated things,” he said. “So a sore arm reaction is good, because that means it’s working for you.”

More safety data, which can only be garnered from monitoring trial participants over a longer term, is needed to judge further, he says.

WHAT’S NEXT, AND WHAT DOES IT MEAN FOR CANADA?

The Food and Drug Administration (FDA) is meeting to discuss Pfizer’s emergency use authorization request on Dec. 10, which means a vaccine rollout could happen in the United States within the next month.

But the vaccines would need approval from Health Canada in order to get them here.

Health Canada’s website says it will review authorization submissions from companies to determine “evidence of safety, efficacy and manufacturing quality for each vaccine.”

Canada locked in a supply of potential vaccine candidates when it signed agreements with a number of pharmaceutical companies, including AstraZeneca, Pfizer and Moderna months ago, and that should accelerate a rollout when ready.

READ MORE: First COVID vaccines could arrive in U.S. on Dec. 12

But the actual time frame will depend on when these drug companies can show enough safety data to move forward, Brown said.

Grindrod expects a viable candidate to be approved quickly after safety and efficacy can be shown.

“We might see early 2021 and it’s not clear whether that’s January or February or around that time,” she said. “From there, as we get more doses and more vaccines are approved, then we may see a broader population getting vaccinated. But it’s hard to say when that will happen.”

Melissa Couto Zuber, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvideo

Just Posted

Students at Creston Valley Secondary School put together an art installation of a replica residential school room. (Photo by Kelsey Yates)
Creston students create art installation of residential school room

The replica was decorated with a small bed, school uniform, and notes written with pleas for help

A tent housing a mobile vaccination clinic. (Interior Health/Contributed)
Second dose vaccinations accelerating throughout region: Interior Health

To date, more than 675,000 doses have been administered throughout the region

The Food Recovery Program has pivoted to more meal production during this pandemic year. Submitted file
Kimberley Food Recovery Program producing more meals during pandemic

This past Monday, June 14, Shannon Grey-Duncan from the Kimberley Food Recovery… Continue reading

Prince Charles Secondary School
School District 8 votes in favour of name change for Secondary School in Creston

In an act of reconciliation, a new name will be chosen for Prince Charles Secondary School

Kootenay-Columbia MP Rob Morrison. Photo courtesy Conservative Party of Canada.
MP Morrison appointed to parliamentary national security committee

Kootenay-Columbia parliamentarian one of five candidates appointed to national security committee

Local environmental group Mainstreams conducting more work along the banks of Mark Creek. Paul Rodgers photos.
WATCH: Mainstreams continues riparian and aesthetic enhancement project along Mark Creek

Local environmental organization Mainstreams was back along the banks of Mark Creek… Continue reading

FILE – A science class at L.A. Matheson Secondary in Surrey, B.C. on March 12, 2021. (Lauren Collins/Surrey Now Leader)
Teachers’ union wants more COVID transmission data as B.C. prepares for back-to-school

BCTF says that details will be important as province works on plan for September

Provincial health officer Dr. Bonnie Henry outlines B.C.’s COVID-19 restart plan, May 25, 2021, including larger gatherings and a possible easing of mandatory masks on July 1. (B.C. government photo)
B.C. records 120 new COVID-19 cases, second vaccines accelerating

Lower Pfizer deliveries for early July, Moderna shipments up

A Heffley Creek peacock caught not one - but two - lifts on a logging truck this month. (Photo submitted)
Heffley Creek-area peacock hops logging trucks in search of love

Peacock hitched two lifts in the past month

Join Black Press Media and Do Some Good
Join Black Press Media and Do Some Good

Pay it Forward program supports local businesses in their community giving

The Calgary skyline is seen on Friday, Sept. 15, 2017. THE CANADIAN PRESS/Jeff McIntosh
2 deaths from COVID-19 Delta variant in Alberta, 1 patient was fully immunized

Kerry Williamson with Alberta Health Services says the patients likely acquired the virus in the hospital

The first suspension bridge is the tallest in Canada, with a second suspension bridge just below it. The two are connected by a trail that’s just over 1 km. (Claire Palmer photo)
PHOTOS: The highest suspension bridges in Canada just opened in B.C.

The Skybridge in Golden allows visitors to take in views standing at 130 and 80 metres

BC Green Party leader and Cowichan Valley MLA Sonia Furstenau introduced a petition to the provincial legislature on Thursday calling for the end of old-growth logging in the province. (File photo)
BC Green leader Furstenau introduces old-growth logging petition

Party calls for the end of old-growth logging as protests in Fairy Creek continue

B.C. Premier John Horgan leaves his office for a news conference in the legislature rose garden, June 3, 2020. (B.C. government photo)
B.C. premier roasted for office budget, taxing COVID-19 benefits

Youth addiction law that triggered election hasn’t appeared

Most Read